Calcium controlled activation of platelets via electrical stimulation

Patent metadata

Field	Value
Publication number	US-10633645-B2
Application number	US-201514984988-A
Country	US
Kind code	B2
Filing date	Dec 30, 2015
Priority date	Dec 30, 2015
Publication date	Apr 28, 2020
Grant date	Apr 28, 2020

Abstract

The present disclosure relates to the generation of an activated platelet product in which one or more of the presence or absence of clots, the timing of clot formation (if present), and/or the mechanical strength of clots (if present) is controlled by the presence or concentration of calcium ions during the activation process. In certain embodiments, the calcium ion concentration is controlled in the presence of pulsed electric fields or a chemical activator (e.g., thrombin) as part of the activation process.

First claim

The invention claimed is:

1. A method for generating an activated product comprising:
preparing a platelet-rich plasma (PRP) sample for activation by adding a reagent comprising calcium ions to the PRP sample, wherein the prepared PRP sample comprises a first calcium ion concentration, wherein the first calcium ion concentration is selected based upon target levels of one or more growth factors and clotting characteristics in the activated product generated using the PRP sample, the clotting characteristics comprising a time of formation of a clot or mechanical strength of the clot, or any combination thereof;
positioning the prepared PRP sample between electrodes of an electromagnetic stimulation apparatus;
specifying a set of electrical pulse parameters based upon the first calcium ion concentration and the clotting characteristics; and
exposing the prepared PRP sample to one or more electrical pulses generated in accordance with values of the set of electrical pulse parameters, wherein the PRP sample, when exposed to the one or more electrical pulses, yields the activated product comprising target levels of the one or more growth factors and the clotting characteristics.

2. The method of claim 1 , wherein the same set of electrical pulse parameters but different concentrations of calcium ions yield differences in the clotting characteristics in the activated product.

3. The method of claim 1 , wherein the PRP sample comprises a platelet gel, a platelet suspension, or a whole blood sample.

4. The method of claim 1 , wherein relative levels of the growth factors in the activated product are determined by one or both of the set of electrical pulse parameters and the first calcium ion concentration.

5. The method of claim 1 , wherein adding the reagent comprises adding CaCl 2 to an anticoagulant-treated PRP sample, and wherein the first calcium ion concentration is in a range of about 2.5 mM to about 20 mM.

6. The method of claim 1 , wherein the first calcium ion concentration is selected from 2.5 mM, 5.0 mM, 7.5 mM, 10 mM, 15 mM, 20 mM, or 25 mM CaCl 2 being added to the anticoagulant-treated PRP sample.

7. The method of claim 1 , wherein the first calcium ion concentration is selected based on the time of formation of the clotting.

8. The method of claim 1 , wherein the first calcium ion concentration is selected based on a clot mechanical strength.

9. The method of claim 1 , wherein the growth factors comprise epidermal growth factor (EGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), or platelet factor 4 (PF4), or any combination thereof.

10. A method for generating an activated product comprising:
preparing an anticoagulant-treated platelet-rich plasma (PRP) sample for activation;
adding calcium ions to the PRP sample to achieve a calcium ion concentration selected from a range of possible concentrations, wherein the concentration is selected based upon target levels of one or more growth factors to be present in an activated product composition generated using the PRP sample and wherein one or more clotting characteristics are also determined by the calcium ion concentration; and exposing
the PRP sample to electrical activation stimulus, wherein the PRP sample, when exposed to the electrical activation stimulus, yields an activated product composition comprising the one or more growth factors at the target levels and the one or more clotting characteristics, wherein varying the calcium ion concentration without varying the electrical activation stimulus changes one or both of the absolute or relative levels of the one or more growth factors.

11. The method of claim 10 , wherein adding calcium ions to the PRP sample comprises adding CaCl 2 to the PRP sample in a concentration in the range of about 2.5 mM to about 20 mM.

12. The method of claim 10 , wherein the concentration of calcium ions is selected from a plurality of possible concentrations corresponding to 2.5 mM, 5.0 mM, 7.5 mM, 10 mM, 15 mM, 20 mM, or 25 mM CaCl 2 being added to the PRP sample.

13. The method of claim 10 , wherein a first calcium concentration that is less than a second calcium ion concentration results in an initial clot formation that is quicker than that observed at the second calcium ion concentration.

14. The method of claim 10 , wherein a first calcium concentration that is less than a second calcium ion concentration results in a clot mechanical strength that is less than that observed at the second calcium ion concentration.

15. A method for controlling clot mechanical strength in a platelet gel, comprising:
determining a prospective mechanical strength of one or more clots to be generated in the platelet gel, wherein the prospective mechanical strength is greater than what would be observed by generating the platelet gel using thrombin alone; determining target levels of one or more growth factors; based
on the prospective mechanical strength and target levels of one or more growth factors, selecting a calcium ion concentration based upon the target levels of one or more growth factors and corresponding to the prospective mechanical strength from among a plurality of calcium ion concentrations; and generating;
the platelet gel by activating a platelet-rich plasma (PRP) sample comprising calcium ions at the selected calcium ion concentration, wherein the PRP sample is activated using electrical stimulus, and wherein the platelet gel comprises clots that, once formed, have the prospective mechanical strength and comprise the target levels of the one or more growth factors.

16. The method of claim 15 , wherein, for the plurality of calcium ion concentrations, higher calcium ion concentrations correspond to greater mechanical strength of the clots.

17. The method of claim 15 , wherein the plurality of calcium ion concentrations is within a range corresponding to what is generated by addition of about 2.5 mM to about 20 mM CaCl 2 to the PRP sample.

18. The method of claim 17 , wherein the calcium ion concentration is selected from the plurality of possible concentrations corresponding to 2.5 mM, 5.0 mM, 7.5 mM, 10 mM, 15 mM, 20 mM, or 25 mM CaCl 2 being added to the PRP sample.

Assignees

• Gen Electric

Inventors

• Neculaes Vasile Bogdan
• Torres Andrew Soliz
• Klopman Steve Lambert

Classifications

• A61K38/18 Primary

  Growth factors; Growth regulators · CPC title

• C12N13/00 Primary

  Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves · CPC title

• A61K41/00

  Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations} · CPC title

• A61K33/06

  Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay} · CPC title

• C12N5/0644

  Platelets; Megakaryocytes · CPC title